LEMD1 and cancer: LEM domain containing 1 (LEMD1, also reported as CT50 and LEMP-1) is identified to be a novel candidate gene of the cancer-testis antigens (CTAs) family with several features of ideal biotargets for cancer immunotherapy and early detection due to the characteristics that are normally present in the testis and aberrantly expressed in multiple cancer cells [4,5].